Bone-Bound Bisphosphonates Inhibit Proliferation of Breast Cancer Cells

Park, Young Eun; Bava, Usha; Lin, Jianming; Cornish, Jillian; Naot, Dorit; Reid, Ian R.

doi:10.1007/s00223-019-00590-5

Cited by 7 publications

(3 citation statements)

References 59 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Except cytostatics, the chemical interactions like hydrogen bonding have also been used in self-assembled construction of nanophotosensitizers for cancer with longer local retention and tumor killing effect [ 41 , 42 ]. Similar interactions of other biomolecules, particularly 3rd generation bisphosphonates like zoledronic acid, known to bind to HA have been widely used systemically for bone tumor inhibition [ 43 ]. HA-binding antimicrobial peptides have been designed for bone infections [ 44 ].…”

Section: Discussionmentioning

confidence: 99%

Bone mineral: A trojan horse for bone cancers. Efficient mitochondria targeted delivery and tumor eradication with nano hydroxyapatite containing doxorubicin

Liu

Nadeem

Sebastian

et al. 2022

Materials Today Bio

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Bone mineral: A trojan horse for bone cancers. Efficient mitochondria targeted delivery and tumor eradication with nano hydroxyapatite containing doxorubicin

Liu

Nadeem

Sebastian

et al. 2022

Materials Today Bio

View full text Add to dashboard Cite

“…An explanation advanced by the authors of the study was that “reproductive hormones can inhibit bisphosphonate efficacy against cancer cells in the bone” . BPs were shown to be effective growth inhibitors in vitro , using a simple, hormone-free, set of cultures of immortalized breast cancer cells (lines MDA-MB-231, MCF-7, and Hs 578T) against which the compounds clodronate, pamidronate, alendronate, ibandronate, and zoledronic acid displayed potencies directly proportional to their antiresorptive activities. , The conditions in which such activity can be expressed in human patients remain the subject of further investigation. (ii) In women with advanced stages of breast cancer, particularly those having already metastases in the bones, BPs offer an important protection against complications, reducing the risk of SREs by 14% and bone pain in roughly half of the cases, as shown in a systematic review of randomized controlled trials.…”

Section: Bisphosphonates In Clinical Practicementioning

confidence: 99%

Bisphosphonates, Old Friends of Bones and New Trends in Clinics

2021

View full text Add to dashboard Cite

Bisphosphonates, used for a long time in osteoporosis management, are currently the target of intensive research, from pre-formulation studies to more advanced stages of clinical practice. This review presents an overview of the contributions of this family of compounds to human health, starting with the chemistry and clinical uses of bisphosphonates. Following this, their pharmacology is described, highlighting administration-borne handicaps and undesirable effects. The last three sections of the review describe the research efforts that seek to curb delivery-related issues and expand bisphosphonate use. Innovative routes and strategies of administration, such as nano-encapsulation for oral intake or injectable cements for local or in-bone delivery are presented, as well as the latest results of case studies or preclinical studies proposing new therapeutic indications for the clinically approved bisphosphonates. Finally, a selection of anti-infectious bisphosphonate new drug candidates is shown, with focus on the molecules reported in the last two decades.

show abstract

“…More recently, Perrone et al observed benefits in disease-free survival in premenopausal women undergoing ovarian function suppression treated with adjuvant bisphosphonates compared with women who did not receive adjuvant bisphosphonates [218]. In vitro study demonstrated that bisphosphonate-coated bovine bone slices reduced MCF-7 luminal A and MDA-MB-231 triple-negative breast cancer cell lines abilities to adhere and proliferate compared with controls without bisphosphonate-coating [219]. Interestingly, Buranrat et al have also demonstrated that bisphosphonates reduced migratory abilities by inducing cell cycle arrest and increasing apoptosis of the MCF-7 cell line [220].…”

Section: Bisphosphonatesmentioning

confidence: 99%

Breast Cancer and Microcalcifications: An Osteoimmunological Disorder?

Clemenceau

Michou

Diorio

et al. 2020

IJMS

View full text Add to dashboard Cite

The presence of microcalcifications in the breast microenvironment, combined with the growing evidences of the possible presence of osteoblast-like or osteoclast-like cells in the breast, suggest the existence of active processes of calcification in the breast tissue during a woman’s life. Furthermore, much evidence that osteoimmunological disorders, such as osteoarthritis, rheumatoid arthritis, or periodontitis influence the risk of developing breast cancer in women exists and vice versa. Antiresorptive drugs benefits on breast cancer incidence and progression have been reported in the past decades. More recently, biological agents targeting pro-inflammatory cytokines used against rheumatoid arthritis also demonstrated benefits against breast cancer cell lines proliferation, viability, and migratory abilities, both in vitro and in vivo in xenografted mice. Hence, it is tempting to hypothesize that breast carcinogenesis should be considered as a potential osteoimmunological disorder. In this review, we compare microenvironments and molecular characteristics in the most frequent osteoimmunological disorders with major events occurring in a woman’s breast during her lifetime. We also highlight what the use of bone anabolic drugs, antiresorptive, and biological agents targeting pro-inflammatory cytokines against breast cancer can teach us.

show abstract

Bone-Bound Bisphosphonates Inhibit Proliferation of Breast Cancer Cells

Cited by 7 publications

References 59 publications

Bone mineral: A trojan horse for bone cancers. Efficient mitochondria targeted delivery and tumor eradication with nano hydroxyapatite containing doxorubicin

Bone mineral: A trojan horse for bone cancers. Efficient mitochondria targeted delivery and tumor eradication with nano hydroxyapatite containing doxorubicin

Bisphosphonates, Old Friends of Bones and New Trends in Clinics

Breast Cancer and Microcalcifications: An Osteoimmunological Disorder?

Contact Info

Product

Resources

About